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survival was 100 and 90%, respectively. Two patients experi-
enced a subdural hematoma (SDH), which in both cases re-
solved without sequelae. After careful consultation of the 
potential risks and benefits, all patients as well as a safety 
cohort of 9 subsequent cases decided to continue the ima-
tinib therapy. After adjusting the target international nor-
malized ratio (INR) to around 2.0, no further cases of SDH 
occurred during 50 patient-years.  Conclusions: Long-term 
treatment with imatinib may improve the functional class 
and quality of life. Single cases might even attain hemody-
namic remission. The occurrence of 5% SDH per patient-
years is concerning. However, adjusting the INR to around 
2.0 might obviate this complication.  © 2015 S. Karger AG, Basel 
 Introduction 
 There has been considerable expansion of the thera-
peutic options for patients suffering from pulmonary ar-
terial hypertension (PAH)  [1] . While in the past vasocon-
striction has been the main target, antiproliferative strat-
egies to reverse vascular remodeling have emerged as an 
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 Abstract 
 Background: Antiproliferative strategies have emerged as a 
potential therapeutic option for pulmonary arterial hyper-
tension (PAH).  Objective: To evaluate the long-term efficacy 
and safety of imatinib.  Methods: This is an observational 
study of 15 patients with idiopathic PAH (n = 13) or PAH as-
sociated with connective tissue disease (n = 2) treated off-
label with imatinib 400 mg daily. Pulmonary hypertension-
specific therapy was established in all patients (triple thera-
py in 10, dual therapy in 3, and monotherapy in 2 patients). 
 Results: After 6 months, improvement in hemodynamics 
(p < 0.01), functional class (p = 0.035), and quality of life 
(p = 0.005) was observed. After a median follow-up of 37 
months, there was a sustained improvement in functional 
class (p = 0.032), quality of life (p = 0.019), and echocardio-
graphic parameters of right ventricular function (p < 0.05). 
Three patients (20%) presented with completely normal 
echocardiography, absent tricuspid regurgitation, and nor-
mal pro-brain natriuretic peptide levels, indicative of ‘hemo-
dynamic remission’. Of note, however, only 1 case was as-
sessed by invasive hemodynamics. The overall 1- and 3-year 
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important concept in the management of this rare and 
still often fatal disease. The 3 targeted pathways hereto-
fore, i.e. prostaglandins, endothelin receptor antagonists, 
and phosphodiesterase-5 inhibitors, have – to a variable 
extent – some antiproliferative properties  [2] . However, 
prevention or treatment of pulmonary arterial remodel-
ing has been addressed almost exclusively in experimen-
tal settings and no direct evidence of such effects in hu-
mans has been demonstrated.
 Among several growth factors involved in the abnor-
mal migration and proliferation of pulmonary smooth 
muscle cells, platelet-derived growth factor (PDGF) has 
been identified as a key mediator in the pathogenesis of 
PAH. More than 10 years ago, Humbert et al.  [3] were 
able to detect an increased expression of PDGF A-chain 
mRNA in the lung samples of 13 PAH patients. Subse-
quently, these findings have been confirmed by several 
other groups  [4–7] . PDGF has the ability to induce the 
migration and proliferation of smooth muscle cells and 
fibroblasts and represents an important factor for the 
progression of fibroproliferative disorders including 
PAH  [8] .
 In rats with monocrotaline-induced pulmonary hy-
pertension, Schermuly et al.  [7] demonstrated that ad-
ministration of imatinib decreased PDGF-B expression 
in the pulmonary vasculature and prevented phosphory-
lation of the PDGF receptor. Treatment with imatinib 
starting 28 days after induction of the disease resulted in 
reverse remodeling with near normalization of the vascu-
lar muscularization and medial wall thickness. The ele-
vated right ventricular pressure and right heart hypertro-
phy were drastically improved. Imatinib treatment result-
ed in 100% survival compared to only 50% in placebo-
treated rats.
 In light of these findings, the same group initiated ima-
tinib therapy in a patient who had a deteriorating course 
despite triple therapy for idiopathic PAH yet refused lung 
transplantation  [9] . Three months after the start of ima-
tinib, the patient showed a dramatic improvement in 
functional class, 6-min walk distance (6MWD), and pul-
monary hemodynamics. Subsequently, 3 other cases with 
a comparable response to imatinib have been reported 
 [10, 11] .
 In the context of these preliminary data, we com-
menced an observational study to evaluate the efficacy 
and safety of long-term imatinib treatment in patients al-
ready on targeted PAH therapy. In order to thoroughly 
assess their clinical course, we performed a comprehen-
sive follow-up of each patient, including a full hemody-
namic evaluation at baseline and after 6 months of ther-
apy. Herein, we present the clinical course of our first 
consecutive 15 patients who completed at least a 6-month 
treatment period.
 Materials and Methods 
 The current observational study was conducted at the Univer-
sity Hospital Zurich beginning in February 2008. PAH was diag-
nosed according to international guidelines based on the presence 
of a mean pulmonary artery pressure (mPAP) >25 mm Hg and a 
pulmonary artery occlusion pressure <15 mm Hg  [12] . The inclu-
sion criteria for the current observational study were as follows: 
patients already on targeted PAH combination treatments and not 
having reached our therapeutic goals [adapted from the Paris Pul-
monary Hypertension Program; O. Sitbon, pers. commun.], which 
consist of a cardiac index >2.8 liters/min/m 2 , NYHA functional 
class II, and a 6MWD >400 m. This observational study was for-
mally approved by the local ethics committee, although according 
to Swiss regulation practice there is no need for ethical approval if 
off-label use of drugs is applied in orphan diseases.
 Herein we describe our first 15 consecutive cases. The median 
follow-up time was 37 months [interquartile range (IQR) 28–46; 
range 8–60]. One case has already been presented elsewhere  [13] . 
Imatinib was started at a dose of 200 mg/day, which was increased 
to 400 mg/day after about 2 weeks in all patients. 
 Baseline assessment and follow-up after 6 months of therapy 
included a thorough clinical examination, assessment of the 
NYHA functional class and 6MWD according to international 
guidelines  [14] , a full invasive hemodynamic evaluation, and ex-
ploration of the health-related quality of life using the German 
version of the CAMPHOR questionnaire  [15] . This score ranges 
from 0 (best) to 80 (worst). The questionnaire could not be applied 
in 5 patients for linguistic reasons. 
 At the last time point of follow-up, only 1 patient underwent 
an invasive hemodynamic assessment  [13] . In all other patients the 
mPAP was calculated from the systolic pressure gradient between 
the right ventricle and the right atrium determined by echocar-
diography according to the formula of Chemla et al.  [16] , i.e. 
mPAP = 0.61    ·    (RV – RA + 5) + 2. Data on tricuspid annular plane 
systolic excursion and fractional area change were not available in 
5 patients since their echocardiography was not performed at our 
institution.
 After becoming aware of the fact that imatinib may contribute 
to the occurrence of subdural hematoma (SDH) in September 2011 
 [17] , we decided firstly to keep the INR around 2.0, and secondly 
to obtain written informed consent from the patients willing to 
continue imatinib therapy, emphasizing the risk of SDH.
 To thoroughly assess the willingness of our patients to con-
tinue imatinib therapy despite being aware of the increased risk of 
SDH, we confronted them with a worst-case scenario concerning 
the morbidity and mortality of SDH. For that purpose, we per-
formed a comprehensive literature review of more than 4,000 pa-
tients suffering from SDH. To calculate the 95% CI for morbidity 
and mortality due to SDH given in the literature, the exact Poisson 
confidence limit was used. 
 The analysis revealed a weighted average morbidity and mor-
tality of SDH of 0.7% (95% CI 0.06–1; range 0–8) and 0.4% (95% 
CI 0.2–0.6; range 0–3), respectively  [18–21] . Patients were con-
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fronted with a worst-case scenario of SDH by using not the upper 
95% CI but the upper ranges, i.e. an annual morbidity of up to 8% 
and a mortality of up to 3%, respectively.
 The greatest difficulty was in presenting to the patients the usu-
al clinical course of PAH. Most patient series give only data on 
survival and NYHA functional class, which would not have been 
illustrative enough. In addition, 10 patients were already on triple-
drug therapy, including 6 patients on intravenous prostanoids. 
Moreover, 5 patients were aged >65 years, and another 5 would 
even have been candidates for lung transplantation according to 
the current guidelines. In fact there are no data whatsoever about 
the usual clinical course for such a seriously diseased patient pop-
ulation.
 Furthermore, we included our next 9 cases followed up until 
June 2014 to perform an extended safety assessment of imatinib in 
PAH. Thereby we could increase our overall observation time up 
to 76 patient-years. The clinical course of these 9 patients, how-
ever, was not assessed as comprehensively as that of the initial co-
hort.
 Data are given as medians with interquartile ranges, total rang-
es, or 95% CI as appropriate. Statistical analysis of continuous vari-
ables was performed using the Wilcoxon signed-rank test and the 
Kruskal-Wallis test as appropriate. Changes in NYHA functional 
class were assessed by comparing the number of patients in NYHA 
class I–II and III–IV using Fisher’s exact test. p < 0.05 was consid-
ered statistically significant.
 Results 
 Efficacy Parameters at 6 Months 
 The demographics, treatment with targeted therapies, 
and details of imatinib therapy of the 15 consecutive pa-
tients are shown in  table 1 . Notably, 10 patients were al-
ready on triple-drug therapy, including parenteral pros-
tanoids in 6 patients. Three patients were receiving com-
bination therapy with bosentan and sildenafil, and 2 
patients with features of pulmonary veno-occlusive dis-
ease tolerated neither sildenafil nor prostanoids. 
 All patients completed the 6-month treatment period. 
The main results in all of these 15 patients at baseline and 
after 6 months are presented in  table 2 . The 6MWD re-
mained at a median of 458 m (IQR 411–520). The NYHA 
functional class improved significantly (p = 0.035). Seven 
patients improved by 1 class, and overall 7 patients were 
in class II after 6 months ( fig. 1 ). None of the patients de-
teriorated or remained in class IV. In addition, we ob-
served a significant improvement (by 9 points) in health-
related quality of life (p = 0.005).
 All except 1 patient underwent a complete invasive he-
modynamic assessment by right heart catheterization at 
baseline and after 6 months of therapy ( table 2 ). These 
data showed a significant improvement in mPAP, cardiac 
index, pulmonary vascular resistance (PVR), and mixed 
venous oxygen saturation. Only 1 patient did not undergo 
right heart catheterization after 6 months. However, 
when assessed after 42 months on imatinib, and notably 
without any other changes in therapy, her PVR had de-
creased from 2,078 dyn       ·       s       ·       cm –5 at baseline to 970 
dyn    ·    s    ·    cm –5 .
 Long-Term Outcome 
 All patients completed the first 6-month period on 
imatinib therapy and continued it thereafter, except for 1 
patient who definitely stopped imatinib after 8 months 
because of mild diffuse musculoskeletal complaints and 
the lack of a subjective benefit. 
 Two patients temporarily interrupted imatinib thera-
py because of the lack of a subjective benefit (n = 1) and 
nonspecific side effects (n = 1). However, both of them 
resumed imatinib therapy after 15 and 35 months, re-
spectively, because of a deteriorating clinical course. No-
tably, at the time of discontinuing imabinib, the former 
patient had become oxygen independent and her CAM-
PHOR score had improved from 20 to 13. Only a few 
months later, the patient again needed supplemental oxy-
gen (4 liters/min) and her CAMPHOR score deteriorated 
 Table 1.  Demographics, pretreatment, and details of imatinib 
therapy
Patients 15
Age, years 53 (39 – 69)
Range 22 – 74
Females 11
Diagnosis
Idiopathic PAHa 13
Connective tissue disease 2
Duration of targeted therapy before
imatinib, months 43 (22 – 71)
Range 6 – 97
Targeted therapy at imatinib baseline
Bosentan 2
Bosentan and sildenafil 3
Bosentan, sildenafil, and inhaled iloprost 4
Bosentan, sildenafil, and intravenous iloprost 6
Follow-up time of imatinib therapy, months 37 (28 – 46)
Range 8 – 60
Time to permanent cessation of imatinib therapy, 
monthsb 8
Length of temporary interruption of imatinib, 
monthsc 15, 35
Values are presented as medians (IQR) or numbers unless 
otherwise stated. a Features of veno-occlusive disease in 2 patients. 
b In 1 patient. c In 2 patients.
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to 30 points. In retrospect, her symptoms leading to the 
interruption of imatinib could have been attributed to an 
incipient nondiagnosed diabetes mellitus.
 All 14 patients were followed up for 37 months (IQR 
28–46; range 8–60). The 6MWD stabilized at a median of 
455 m (IQR 412–550). Ten patients (71%; 95% CI 45–88) 
had a 6MWD >400 m at the last follow-up visit. The im-
provement in NYHA functional class remained signifi-
cant (p = 0.032). Seven patients (50%; 95% CI 27–73) were 
still in functional class I–II at that time (p = 0.032).
 As shown in  figure 2 , health-related quality of life as-
sessed by the CAMPHOR questionnaire further im-
proved to 9 points (IQR 7–27; p = 0.019).
 Taken as a whole, the mPAP remained 7 mm Hg low-
er compared to baseline, i.e. 46 mm Hg (IQR 31–58), but 
this did not reach statistical significance (p = 0.14). How-
 Table 2. Efficacy parameters before and after 6 months of imatinib therapy (n = 15)
Characteristics Baseline After 6 months of
imatinib therapy
p
6MWD, m 469 (413 – 514) 458 (411 – 520) 0.820
NYHA class (II/III/IV), n 1/13/1 7/8/0 0.035
CAMPHOR score 29 (20 – 44) 20 (11 – 33) 0.005
Heart rate, beats/min 80 (74 – 89) 82 (76 – 89) 0.950
Mean blood pressure, mm Hg 82 (78 – 85) 80 (76 – 87) 0.682
Right heart catheterization (n = 14)a
Right atrial pressure, mm Hg 7 (4 – 9) 6 (4 – 10) 0.812
Mean pulmonary artery pressure, mm Hg 53 (42 – 63) 42 (32 – 56) 0.006
Cardiac index, l/min/m2 2.8 (2.6 – 2.9) 3.4 (3.0 – 4.3) 0.008
Pulmonary vascular resistance, dyn•s•cm–5 644 (585 – 854) 429 (318 – 526) <0.001
Pulmonary artery occlusion pressure, mm Hg 11 (7 – 13) 10 (8 – 11) 0.734
Arterial oxygen saturation, % 90 (89 – 92) 94 (91 – 95) 0.115
Mixed venous oxygen saturation, % 62 (58 – 67) 69 (65 – 72) 0.006
 Values are presented as medians (IQR) unless otherwise stated. a One patient had no right heart catheterization 
after 6 months, but after 42 months on imatinib her pulmonary vascular resistance decreased from 2.078 
dyn•s•cm–5 at baseline to 970 dyn•s•cm–5.
0
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BL 6 months FU
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)
 Fig. 1. Improvement in functional class from baseline (BL) to 6 
months and the last follow-up visit (FU). 
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p = 0.019
 Fig. 2. Course of the health-related quality of life assessed by the 
CAMPHOR questionnaire. Data are given as medians and IQR. 
BL = Baseline; FU = last follow-up visit. The questionnaire could 
not be applied in 5 patients for linguistic reasons.  
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ever, after a treatment period of 30, 32, and 44 months, 
respectively, in 3 cases the mPAP assessed invasively (n = 
1) or calculated from the echocardiographic pressure gra-
dient (n = 2) decreased by >30 mm Hg to near-normal or 
normal levels ( fig. 3 ), i.e. from 53 to 23 mm Hg, from 63 
to 28 mm Hg, and from 63 to 31 mm Hg, respectively. The 
clinical course of the first patient has been described in 
detail elsewhere  [13] . The latter 2 patients, in whom the 
mPAP was calculated from the systolic pressure gradient 
between the right ventricle and the right atrium, showed 
a completely normal echocardiography during follow-up 
without a measurable pressure gradient due the absence 
of tricuspid regurgitation. In addition, the levels of pro-
brain natriuretic peptide (proBNP) were found to be nor-
malized in all 3 patients. Though we had no invasive mea-
surements in the latter 2 cases, these data taken as a whole 
may be indicative of ‘hemodynamic remission’ in 3 pa-
tients (20%; 95% CI 8–48).
 In particular, there was a striking improvement in 
right ventricular function, which was assessed in 10 cases. 
The tricuspid annular plane systolic excursion and the 
fractional area change increased from 16 mm (IQR 14–
18) to 21 mm (IQR 19–25; p = 0.01) and from 20% (IQR 
16–26) to 35% (IQR 29–42; p = 0.025), respectively ( fig. 4 ). 
Both of these 2 parameters normalized completely in 8 
out of 10 patients (80%; 95% CI 50–94).
 To compare the short-term hemodynamic effects with 
the long-term clinical parameters shown in  table  3 , we 
correlated them with the change in PVR within the first 6 
months. However, except for a marginally modest Pear-
son’s r for the 6MWD (r = 0.54) and the CAMPHOR (r = 
0.50), there was no relevant correlation whatsoever. Only 
1 patient had a significant hemodynamic improvement, 
i.e. a decrease in mPAP of >10 mm Hg to <40 mm Hg. She 
belonged to the hemodynamic-remission group.
 Three patients died after having been on targeted ther-
apy for 50, 52, and 58 months, respectively, and on ima-
tinib for 30, 46, and 47 months, respectively. The 2 pa-
tients who remained in NYHA functional class IV died 
after a rapid downhill course due to right heart failure. 
Interestingly, both patients showed all features known to 
be relatively specific for pulmonary veno-occlusive dis-
ease (i.e. a very low diffusion capacity, hypoxemia, and 
characteristic signs on chest computed tomography).
 The third patient committed suicide because of a ma-
jor depressive disorder. He was censored at that time. 
Hence, the overall 1- and 3-year survival was 100 and 
90%, respectively.
 Safety and Tolerability 
 Imatinib was generally well tolerated. The following 
complaints were noted: nausea (n = 4), arthralgia (n = 4), 
edema (n = 3), abdominal pain (n = 2), headache (n = 2), 
and dizziness (n = 1). One abnormality attributable to 
imatinib was a significant decrease in the total hemoglo-
bin level from 13.7 g/dl (IQR 13.2–14.4) to 12.6 g/dl (IQR 
12.4–13.6) after 6 months of therapy (p = 0.041), with no 
change thereafter (12.6 g/dl; IQR 11.1–13.8). There was 
no evidence of cardiotoxicity. The pulmonary artery 
wedge pressure did not change during the first 6 months 
( table 2 ), and the left ventricular ejection fraction tended 
to increase from 63% (IQR 60–69) at the initiation of ima-
tinib to 66% (IQR 63–68) at the last follow-up echocar-
diography (p = 0.066;  table 3 ).
 Only after becoming aware of the association between 
imatinib and SDH based on the first presentation of the 
IMPRES data by Hoeper et al.  [17] in September 2011 was 
our attention drawn to 2 cases in our series who suffered 
from spontaneous SDH. 
 The first case occurred after 13 months of imatinib 
therapy in a 70-year-old female without a history of a pre-
ceding trauma. The duration of symptoms was 3 weeks. 
After surgical evacuation, the patient recovered without 
any neurological sequelae. Notably, the patient had suf-
fered from an SDH on the contralateral side 3 years ear-
lier when on oral anticoagulants only. 
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 Fig. 3. Course of the mPAP in 3 patients. Except at baseline (BL) 
and month 6, the mPAP in patients 2 and 3 is based on echocar-
diographic assessments, calculated using the formula of Chemla et 
al.  [16] . In both cases, the last echocardiograms were completely 
normal, with no measurable pressure gradient due to a lack of tri-
cuspid insufficiency. For better visualization, a virtual value of 24 
mm Hg was given at those time points (asterisks). On the right 
side, the corresponding proBNP levels at the last assessment are 
shown as open symbols. 
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 The second patient was a 53-year-old female present-
ing with SDH after 2 months of imatinib therapy. Her 
symptoms started 5 days before the diagnosis when she 
had an INR of 5.4. In addition, at that time she was receiv-
ing continuous intravenous iloprost at a dose of 4.7 ng/
min/kg. No surgical intervention was needed. In both pa-
tients, the oral anticoagulant was stopped but imatinib 
was continued. 
 Hence, the incidence of SDH in the current patient co-
hort was 2 per 37 patient-years (5%; 95% CI 2–18). After 
October 2011, we adjusted the INR to around 2.0, and 
thereafter no further SDH were observed. By the time of 
inclusion of our next 9 patients treated with imatinib, the 
total safety follow-up time had accrued to 50 patient-
years. 
 Patients’ Decision Making 
 After becoming aware of the fact that imatinib by itself 
may contribute to the occurrence of SDH, we discussed 
this issue with our patients still on imatinib (n = 14) and 
oral anticoagulants (n = 12), as well as with the 9 subjects 
in the safety cohort.
 As pointed out in Materials and Methods, the patients’ 
decision making process was conducted by juxtaposing 
the maximum risk to be taken with the minimum poten-
tial benefit of continuing imatinib.
10
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p = 0.01
BL FU
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m
)
p = 0.025
BL FU
20
35
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)
0
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20
30
40
50
 Fig. 4. Improvement in right ventricular function from baseline (BL) and the last follow-up visit (FU). Data are 
given as medians and IQR. The dotted lines indicate normal values. TAPSE = Tricuspid annular plane systolic 
excursion (in mm); fac = fractional area change (in %). Data were not available in 5 patients since their echocar-
diography was not performed at our institution. 
 Table 3. Efficacy parameters at baseline and at the last follow-up examination (n = 14)
Baseline Last
follow-up
p
6MWD, m 469 (413 – 514) 455 (412 – 550) 0.820
NYHA functional class (I/II/III/IV), n
CAMPHOR score
1/12/1
29 (20 – 44)
1/6/5/2
9 (7 – 27)
0.032
0.019
Mean pulmonary artery pressure, mm Hg 53 (42 – 63) 46 (31 – 58)a 0.139
Tricuspid annular plane systolic excursion, mm 16 (14 – 18) 21 (19 – 25) 0.010
Fractional area change, % 20 (16 – 26) 35 (29 – 42) 0.025
Left ventricular ejection fraction, % 63 (60 – 69) 66 (63 – 68) 0.066
Values are presented as medians (IQR) unless otherwise stated. a Calculated from echocardiography using the 
formula of Chemla et al. [16], except for 1 patient who underwent right heart catheterization.
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 Regarding the maximum potential risk due to SDH, 
we confronted the patients with a worst-case scenario us-
ing the upper 95% CI. Hence, from our data mentioned 
above, which are comparable to those of the IMPRES co-
hort  [22] , the maximum annual risk of suffering from an 
SDH was estimated to be 18%. The maximum morbidity 
and mortality were calculated by multiplying this figure 
by the maximum inherent morbidity (8%) and mortality 
(3%) estimated from the literature data, as described in 
Materials and Methods. By rounding up the 95% CI of 
these 2 products, our scenario was an annual morbidity 
due to neurological sequelae of 2% and a mortality rate of 
1%.
 As outlined in Materials and Methods, for the NYHA 
functional class and the 6MWD we could tell our patients 
that they had at least a 25% chance of remaining in NYHA 
functional class I–II (the meaning of which they knew 
well from our standard questionnaire) and a 45% chance 
of retaining a 6MWD >400 m. 
 Confronted with this scenario in a narrative way, all 
patients were willing to take the worst potential risk-ben-
efit ratio in favor of continuing the imatinib therapy. 
They all gave a second written informed consent includ-
ing the issue of SDH. We counseled our patients to a tar-
get INR of around 2.0 and instructed them about the 
symptoms of SDH and the subsequent actions to be tak-
en. 
 Discussion 
 This is, to the best of our knowledge, the first report on 
a case series of long-term imatinib treatment in 15 pa-
tients suffering from far advanced PAH, with two thirds 
of the patients already on a triple targeted therapy includ-
ing 6 cases on intravenous prostanoids. In line with the 
data from the phase II  [23] and phase III  [24] trials, there 
was a significant short-term improvement in functional 
class, health-related quality of life, and hemodynamics. 
The overall 1- and 3-year survival was 100 and 90%, re-
spectively, which, in the context of the advanced stage of 
disease in our patients, is remarkable.
 Over the long-term follow-up of a median of 37 months 
(range 8–60), possibly due to a ceiling effect, the 6MWD 
did not improve but remained at >400 m in 10 patients 
(71%). The NYHA functional class was still I–II in 7 pa-
tients (50%; p = 0.032). Health-related quality of life, as-
sessed by the CAMPHOR questionnaire, steadily im-
proved from 29 points (baseline) to 20 points (after 6 
months of imatinib therapy) and finally to 9 points (at the 
end of follow-up) (p = 0.019). It has to be mentioned that 
there were missing data for 5 patients due to linguistic 
reasons. This, however, should not have negatively influ-
enced the results since 2 of these patients corresponded 
to the 3 cases attaining hemodynamic remission (see be-
low).
 Since we had data on the hemodynamic short-term 
response in 14 patients, we tried to correlate them by us-
ing the PVR as a fixed variable, with the parameters as-
sessed in the long term. All correlations were trivial ex-
cept that with the 6MWD (r = 0.54) and the CAMPHOR 
(r = 0.50). Hence, the short-term hemodynamic response 
could not predict the long-term outcome. 
 Three patients (20%; 95% CI 8–48) normalized their 
hemodynamic parameters assessed by invasive measure-
ments (n = 1) or echocardiography (n = 2). The former 
patient could even be weaned from intravenous pros-
tanoid therapy  [13] . We recognize the important draw-
back insofar as that in the latter 2 cases we only had pres-
sures derived from echocardiography. However, since 
both of them had a completely normal echocardiography 
with normal right ventricular function and no measur-
able pressure gradient on repeated occasions, as well as 
normalization of proBNP levels, these data indicate that 
both patients achieved hemodynamic remission.
 Most notably, 8 out of 10 patients (80%; 95% CI 50–94) 
assessed by echocardiography showed complete normal-
ization of right ventricular function. However, this has to 
be interpreted with caution since only 3 patients had nor-
malized proBNP levels, and we had neither invasive he-
modynamics nor assessments by MRI. 
 The drawbacks of the current study are obvious. First-
ly, due to its open observational design, there was no con-
trol group for comparison with the imatinib-treated pa-
tients. Secondly, after the invasive assessment at 6 months 
of therapy, we had long-term right heart catheterization 
data for only 1 patient with hemodynamic remission. In 
another case, i.e. the sole patient who had no 6-month as-
sessment, right-heart catheterization was repeated after 
42 months on imatinib. By then her PVR had decreased 
from 2,078 dyn    ·    s    ·    cm –5 at baseline to 970 dyn    ·    s    ·    cm –5 .
 In comparison with the IMPRES trial  [24] , the current 
study has (aside from being noncontrolled) two differing 
aspects. Firstly, because of our relatively high treatment 
goals, the 6MWD in our patients was more than 100 m 
higher than in the IMPRES trial. Thus, in contrast to the 
latter, we could not show a significant improvement in 
the 6MWD, possibly due to a ceiling effect. Secondly, the 
PVR in the current cohort was almost 600 dyn     ·     s     ·     cm –5 
lower than in the IMPRES trial. Nine of our patients 
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would not have met the inclusion criterion for the IM-
PRES trial, i.e. a PVR >800 dyn     ·     s     ·     cm –5 . Interestingly, 
even in this subgroup of patients there was a trend toward 
improvement in NYHA functional class (p = 0.14) and 
quality of life (p = 0.07). Although the number of cases 
was very small, this might indicate that imatinib poten-
tially has a beneficial effect also in this less severely dis-
eased patient group.
 Imatinib was generally well tolerated even during 
long-term use. Besides a few transient complaints, there 
was a significant drop in hemoglobin values by 1 g/dl dur-
ing the first 6 months, with no change thereafter. We 
could not detect any signs of cardiotoxicity. Only 1 pa-
tient definitely discontinued imatinib because of nonspe-
cific complaints and the absence of a subjective benefit. 
 However, in September 2011 we became aware, from 
the first presentation of the IMPRES trial  [17] , that, as an 
unexpected and initially unrecognized complication of 
imatinib therapy, there is an increased risk of SDH in 
these patients. The authors of the study reported 2 cases 
of SDH while on imatinib during the randomized trial 
phase  [24] . In addition, another 6 cases were observed in 
the extension study, summing up to an incidence of 4.2% 
per patient-year  [22] . Hence, after receiving this informa-
tion, we immediately took the following two measures. 
 Firstly, we confronted all of our current and the 9 sub-
sequent patients treated with imatinib with a range of po-
tential morbidity and mortality rates due to SDH and the 
potential, but actually unknown, benefits of imatinib. All 
patients were willing to take the worst risk-benefit sce-
nario, and gave written informed consent to continue the 
imatinib therapy. They were explicitly informed about 
the first symptoms of SDH and the immediate measures 
to be taken, i.e. to go to the nearest hospital to perform a 
CT scan.
 Secondly, we decided to retain oral antocoagulants in 
all our patients except in the 2 who had already experi-
enced an SDH. However, we instructed them to keep their 
INR around 2.0. Thereafter, no additional case of SDH 
was observed over a period of 50 patient-years, including 
a safety cohort of an additional 9 patients.
 The issue of oral anticoagulants in patients on imatinib 
is an important topic. A recent consensus paper of the 
working groups on pulmonary hypertension of the Ger-
man-speaking countries  [25] recommended avoiding 
oral anticoagulants in patients on imatinib. The decision 
to continue oral anticoagulants in the current cohort was 
based on our notion of aiming treatment at all 3 main 
pathogenic mechanisms leading to the progression of 
PAH, i.e. thrombosis, vasoconstriction, and proliferation. 
Moreover, in light of the first report of Fuster et al.  [26] , 
which showed improved survival by more than 30% in 
patients on oral anticoagulants but without any targeted 
therapy, it is our belief that oral anticoagulants are crucial 
in these patients. This was recently corroborated by the 
data of the Comparative, Prospective Registry of Newly 
Initiated Therapies for Pulmonary Hypertension (COM-
PERA), where a survival benefit of 10% could be demon-
strated for IPAH patients on oral antocoagulants com-
pared to those without  [27] .
 Of course, we are fully aware that no firm conclusions 
can be drawn from the occurrence of 2 events out of a to-
tal of 15 patients, but these figures are in accordance with 
the IMPRES study and its open-label extension  [22, 24] . 
In this cohort, an overall incidence of SDH of 5.7% (95% 
CI 3–10) was observed during a total of 160 patient-years. 
However, it has to be emphasized that, like in our 2 cases, 
a significant proportion of patients had additional risk 
factors for the development of SDH, like head trauma 
(n = 2), concomitant intravenous prostaglandin therapy 
(n = 2), a history of previous SDH (n = 1), and acute my-
eloid leukemia with thrombocytopenia (n = 1).
 In the normal population, the incidence of SDH is be-
tween 0.0017 and 0.0034% per patient-year (weighted av-
erage 0.0025%)  [28, 29] . It is mainly age dependent, with 
a 10-fold increase in patients aged >65 years (weighted 
average 0.026% per patient-year)  [28–30] . Oral antico-
agulants increase the risk by at least another 10-fold to 
0.22–0.39% per patient-year, depending mainly on the 
level of the INR  [31, 32] . In addition, Louis et al.  [33] 
found an extraordinarily high incidence of 0.35% (95% CI 
0.12–10) SDH cases in PAH patients on intravenous 
prostaglandin therapy and oral anticoagulants.
 Hypothetically, the increased incidence of SDH dur-
ing imatinib therapy might be explained by two facts. 
First, it is well known that tyrosine kinase inhibitors im-
pair platelet aggregation in up to 85% of patients  [34] . In 
addition, imatinib significantly decreases the stromal re-
action and pericyte coverage of microvessels in colonic 
cancer  [35] . This might result in an increase in vascular 
permeability and hence a propensity for bleedings during 
concomitant oral anticoagulants.
 The morbidity and mortality of SDH is quite low and 
may be further reduced by the awareness of the patients 
and the knowledge of the actions to be taken in case of a 
sudden headache. From the upper 95% CI of the inci-
dence of SDH during imatinib therapy (18%, see above) 
multiplied by the upper ranges of its morbidity (8%) and 
mortality (3%) as delineated in Materials and Methods, 
the maximum potential annual risk of SDH is 18%, lead-
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ing to an annual serious morbidity of 1% and a mortality 
of 0.5%.
 In conclusion, despite this being an uncontrolled trial, 
our data emphasize that treatment with imatinib might 
have important benefits and should be considered as an 
additional therapeutic option for patients with severe 
PAH.
 Conclusions 
 Though not powered for efficacy, the current study 
shows that long-term treatment of PAH with imatinib 
may not only stabilize the disease process but also lead to 
a continued improvement in functional class, health-re-
lated quality of life, and normalization of right ventricu-
lar function. In a subset of patients, imatinib therapy 
might result in a hemodynamic remission. The occur-
rence of SDH in 5% of cases per patient-year is concern-
ing. Nevertheless, the risk of significant morbidity and 
mortality from SDH is quite low, and keeping the INR 
around 2.0 might further minimize the risk of its occur-
rence. 
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